Dyne Therapeutics' DYNE-101 shows promising Phase 1/2 results for myotonic dystrophy type 1, with plans for Accelerated ...
How does exercise benefit health? Molecules called exerkines partly regulate its effects and provide therapeutic targets to ...
Shares of Dyne Therapeutics, Inc. (Nasdaq: DYN) plummeted 25% as the biotechnology firm reported early trial data for its experimental therapy for myotonic dystrophy type 1 (DM1), a genetic disorder ...
Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and ...
Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular ...
People with certain mutations in the gene coding for dysferlin develop muscular dystrophy – a group of muscle wasting diseases that affect thousands around the world. Professor Simone Spuler and her ...
People with certain mutations in the gene coding for dysferlin develop muscular dystrophy – a group of muscle wasting diseases that affect thousands around the world. Subscribe to Technology Networks’ ...
A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for ...
A new study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for understanding and ...
We hypothesize that Duchenne muscular dystrophy and autism spectrum disorder/pervasive developmental disorder co-occur with a greater than random frequency. In this study, we set out to reject the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback